© 2022 MJH Life Sciences and NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Two multiple sclerosis experts discuss long-term and real-world data with oral therapies in the treatment of relapsing-remitting multiple sclerosis (RRMS) that was presented at ACTRIMS 2022.
May 12th 2022
Drs Obeidat and Okai, 2 MS experts, discuss impact of relapsing-remitting multiple sclerosis (RRMS) on the quality of life of patients and caregivers.
Dr Okai explains why it is important to initiate MS treatment early and to stay compliant with the treatment.
Cognitive Functioning and Motor Difficulties Identified in Spinal Muscular Atrophy Type 3
Background Factors Drive Elevated Risk of Neonatal Seizures, Epilepsy in Children of Mothers on SSRI/SNRIs
Advocacy’s Part in the Progress in ALS: Matthew B. Harms, MD
This Week on NeurologyLive® — May 16, 2022